Congratulations to uniQure of the Netherlands for EU approval of its gene therapy for familial hyperchylomicronemia, a very rare disease. First gene therapy approval in either the EU or U.S.
See uniQure press relase at:
http://www.uniqure.com/news/167/182/uniQure-s-Glybera-First-Gene-Therapy-Approved-by-European-Commission.html
Best,
Michael Swit
Michael A. Swit, Esq.
Special Counsel, FDA Law Practice
Duane Morris LLP
San Diego
maswit@duanemorris.com
619-744-2215 (direct)
760-815-4762 (cell)